Our study confirmed significant up-regulation of IGFBP2 and predicted a poor outcome for patients as shown in previous studies [17, 31–33], thus providing more evidence for further research into its functional roles during GBM progression. This evidence concerns the gene IGFBP2 and glioblastoma.